Anavex Life Sciences (AVXL)
Market Price (12/28/2025): $3.635 | Market Cap: $312.2 MilSector: Health Care | Industry: Biotechnology
Anavex Life Sciences (AVXL)
Market Price (12/28/2025): $3.635Market Cap: $312.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -140% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -52 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27% | ||
| Key risksAVXL key risks include [1] a negative European regulatory opinion for its lead drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -140% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -52 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27% |
| Key risksAVXL key risks include [1] a negative European regulatory opinion for its lead drug, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
I cannot provide specific key points for Anavex Life Sciences (AVXL) stock movement for the period from 8/31/2025 to today, December 28, 2025, as this timeframe is in the future, and therefore, no factual information about stock performance and contributing factors is available.
Show moreStock Movement Drivers
Fundamental Drivers
The -58.0% change in AVXL stock from 9/27/2025 to 12/27/2025 was primarily driven by a -0.6% change in the company's Shares Outstanding (Mil).| 9272025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 8.66 | 3.64 | -57.97% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 85.38 | 85.90 | -0.61% |
| Cumulative Contribution | � |
Market Drivers
9/27/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| AVXL | -58.0% | |
| Market (SPY) | 4.3% | 16.0% |
| Sector (XLV) | 15.2% | 29.7% |
Fundamental Drivers
The -61.6% change in AVXL stock from 6/28/2025 to 12/27/2025 was primarily driven by a -1.0% change in the company's Shares Outstanding (Mil).| 6282025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.48 | 3.64 | -61.60% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 85.07 | 85.90 | -0.97% |
| Cumulative Contribution | � |
Market Drivers
6/28/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| AVXL | -61.6% | |
| Market (SPY) | 12.6% | 16.4% |
| Sector (XLV) | 17.0% | 27.3% |
Fundamental Drivers
The -69.9% change in AVXL stock from 12/27/2024 to 12/27/2025 was primarily driven by a -1.3% change in the company's Shares Outstanding (Mil).| 12272024 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 12.11 | 3.64 | -69.94% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 84.81 | 85.90 | -1.29% |
| Cumulative Contribution | � |
Market Drivers
12/27/2024 to 12/27/2025| Return | Correlation | |
|---|---|---|
| AVXL | -69.9% | |
| Market (SPY) | 17.0% | 26.6% |
| Sector (XLV) | 13.8% | 26.5% |
Fundamental Drivers
The -55.6% change in AVXL stock from 12/28/2022 to 12/27/2025 was primarily driven by a -10.2% change in the company's Shares Outstanding (Mil).| 12282022 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 8.19 | 3.64 | -55.56% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 77.95 | 85.90 | -10.19% |
| Cumulative Contribution | � |
Market Drivers
12/28/2023 to 12/27/2025| Return | Correlation | |
|---|---|---|
| AVXL | -62.1% | |
| Market (SPY) | 48.0% | 26.8% |
| Sector (XLV) | 17.9% | 24.1% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AVXL Return | 108% | 221% | -47% | 1% | 15% | -65% | 44% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| AVXL Win Rate | 75% | 67% | 58% | 42% | 50% | 33% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| AVXL Max Drawdown | -8% | -4% | -58% | -46% | -64% | -71% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See AVXL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | AVXL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -82.5% | -25.4% |
| % Gain to Breakeven | 472.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -59.0% | -33.9% |
| % Gain to Breakeven | 144.1% | 51.3% |
| Time to Breakeven | 225 days | 148 days |
| 2018 Correction | ||
| % Loss | -80.2% | -19.8% |
| % Gain to Breakeven | 404.8% | 24.7% |
| Time to Breakeven | 678 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -68.7% | -56.8% |
| % Gain to Breakeven | 220.0% | 131.3% |
| Time to Breakeven | 2,394 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Anavex Life Sciences's stock fell -82.5% during the 2022 Inflation Shock from a high on 6/28/2021. A -82.5% loss requires a 472.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
AI Analysis | Feedback
Here are 1-3 brief analogies for Anavex Life Sciences (AVXL):
-
A clinical-stage Biogen, but primarily focused on developing novel treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's.
-
Think of it as a small, high-potential biotech aiming to develop breakthrough drugs for complex neurological disorders, much like Vertex Pharmaceuticals successfully did for cystic fibrosis, but for conditions such as Alzheimer's and Rett Syndrome.
AI Analysis | Feedback
- Blarcamesine (Anavex2-73): An investigational oral drug approved in Europe for the treatment of Rett syndrome and in clinical development for other neurological disorders like Alzheimer's and Parkinson's disease dementia.
- Anavex3-71: An investigational oral drug candidate in early clinical development for various neurological and psychiatric disorders.
AI Analysis | Feedback
Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for neurological and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. As of its latest public filings, Anavex Life Sciences has not yet commercialized any products and, therefore, does not have major customers in the traditional sense of companies or individuals purchasing its products for sale or personal use.
The company's revenue to date has primarily consisted of:
- Government Grants: Funding received from government agencies to support research and development activities, such as from the U.S. National Institutes of Health (NIH) and the Australian Department of Health. These entities provide funding for research and development but are not "customers" purchasing a commercial product.
- Collaboration Revenue: Income generated from strategic partnerships or collaborations related to the development of their drug candidates. These are typically agreements for research, development, or licensing, rather than product sales. Specific collaborators and terms are disclosed in their financial reports.
Anavex Life Sciences anticipates that it will be several years, if ever, before it has a product candidate ready for commercialization and begins to generate revenues from product sales to either companies (e.g., distributors, pharmacies, hospitals) or individuals (patients).
AI Analysis | Feedback
nullAI Analysis | Feedback
Christopher U. Missling, PhD, President and Chief Executive Officer
Dr. Missling has over two decades of experience in the healthcare industry, including roles at large pharmaceutical companies, the biotech industry, and investment banking. Prior to joining Anavex, he served as Chief Financial Officer for Curis, Inc. and ImmunoGen, Inc. He also held positions at Aventis (now Sanofi), where he was involved in financial planning and M&A. Additionally, Dr. Missling worked as an investment banker in the healthcare practice at Deutsche Bank and was Head of healthcare investment banking at Brimberg & Co.
Sandra Boenisch, CPA, Principal Financial Officer and Principal Accounting Officer
Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA) with over 15 years of experience in accounting, audit, and financial reporting across various industries in both the United States and Canada. Before joining Anavex, she served as an independent consultant, providing financial reporting services to a range of public companies. From 2008 to 2012, Ms. Boenisch was employed at BDO Canada LLP, where she advanced from Senior Accountant to Manager, Audit Assurance. She also held the position of VP of Finance at Naked Brand Group, Inc.
Stephan Toutain, MS, MBA, Senior Vice President of Operations
Mr. Toutain brings over 25 years of leadership experience in drug development, general management, operations, commercial development, market access, and sales and marketing, with a specific focus on neurology and orphan drug markets globally. Before joining Anavex, he was the Chief Commercial Officer (CCO) at Interleukin Genetics and worked with Alnylam Pharmaceuticals on its early access program. His previous roles include leading Global Commercial Development for Sarepta Therapeutics and serving as General Manager for Alexion Pharmaceuticals in Europe.
Walter E. Kaufmann, M.D., Chief Scientific Officer
Dr. Kaufmann became Chief Scientific Officer in January 2022, having previously served as the company's Chief Medical Officer. He was the Director of the Center for Translational Research at the Greenwood Genetic Center and held the Ravenel Boykin Curry Chair in Genetic Therapeutics. Dr. Kaufmann has also served as a Simons Investigator at the Massachusetts Institute of Technology's Simons Center for the Social Brain and was a Professor of Neurology at Harvard Medical School. He was also a Professor of Pathology, Neurology, Pediatrics, Psychiatry, and Radiology at the Johns Hopkins University School of Medicine and founded RettSearch, an international consortium for Rett syndrome clinical researchers.
Edward R. Hammond, Chief Medical Officer
Mr. Edward R. Hammond has served as Anavex's Chief Medical Officer since January 2022.
AI Analysis | Feedback
Key Risks to Anavex Life Sciences (AVXL)
Anavex Life Sciences (AVXL) faces significant business risks, primarily centered around regulatory hurdles for its lead drug candidate, blarcamesine, for Alzheimer's disease. The company's reliance on this drug and its inherent financial characteristics as a clinical-stage biotechnology firm also present substantial challenges.1. Regulatory Challenges and Clinical Trial Outcomes
The most immediate and critical risk for Anavex Life Sciences is the regulatory approval process for its lead drug, blarcamesine, particularly in Europe. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recently issued a negative opinion on the marketing authorization application for blarcamesine for early Alzheimer's disease, citing a lack of demonstrated effectiveness and safety, alongside methodological concerns. This setback has led to a substantial decline in the company's stock price and significant uncertainty regarding its European expansion plans. While Anavex plans to request a re-examination of this decision, there is no guarantee of a positive outcome. The biotechnology sector inherently carries risks related to regulatory approvals and the outcomes of clinical trials, and Anavex's experience with blarcamesine highlights this vulnerability. Furthermore, blarcamesine's trial data has been described as inconsistent, with concerns about efficacy and safety, making regulatory success uncertain.2. Pipeline Concentration and Efficacy Doubts
Anavex's business model is heavily reliant on the success of its lead candidate, blarcamesine, with a limited pipeline of other drugs. This high degree of pipeline concentration means that a major setback for blarcamesine significantly impacts the company's overall value and future prospects. For instance, another candidate, ANAVEX2-73, failed its Phase 2/3 trial for Rett syndrome, further emphasizing the risks associated with a concentrated pipeline. Doubts about the efficacy of blarcamesine, particularly regarding its ability to demonstrate functional improvements over placebo and concerns about its safety profile (including dizziness and patient dropouts), contribute to the risk of the drug failing to secure necessary approvals.3. Financial Risks and Dilution
As a clinical-stage biopharmaceutical company, Anavex Life Sciences consistently reports operational losses and has no current revenue. While the company currently has a strong cash position and no reported debt, providing a financial buffer, its research and development expenses remain high. This sustained cash burn, coupled with the absence of revenue, creates an ongoing need for funding. Anavex has a $150 million "at-the-market" (ATM) facility, which, while providing financing flexibility, also poses a significant risk of shareholder dilution as new shares may be issued to raise capital. The company's financial instability is further underscored by a negative revenue trend over the past five years and a low Piotroski F-Score, suggesting potential operational challenges.AI Analysis | Feedback
Approval and market penetration of competing therapies in key indications while Anavex's drug faces regulatory setbacks. Specifically, Acadia Pharmaceuticals' DAYBUE (trofinetide) is approved and marketed for Rett Syndrome in the United States, while Anavex's blarcamesine for Rett Syndrome received a Complete Response Letter (CRL) from the FDA, delaying its potential market entry and creating a significant competitive disadvantage.
AI Analysis | Feedback
Anavex Life Sciences (AVXL) is developing product candidates for several neurodegenerative and neurodevelopmental disorders.
Blarcamesine (ANAVEX®2-73)
- Alzheimer's Disease: The global blarcamesine market, which includes Alzheimer's disease as a primary application, is projected to grow from USD 822.9 million in 2025 to USD 1,082.8 million by 2032. The North American market for blarcamesine is estimated to be over USD 293.77 million in 2025.
- Rett Syndrome: The global market for Rett Syndrome was valued at USD 0.33 billion in 2024 and is projected to reach USD 1.37 billion by 2035. North America holds the largest share of this market.
- Parkinson's Disease Dementia: The broader global Parkinson's disease market across the seven major markets (US, EU4, and Japan) is forecast to grow from USD 3.4 billion in 2023 to USD 7.0 billion by 2033. The Parkinson's Disease Related Dementia Treatment Market in these seven major markets is also expected to grow significantly between 2024 and 2034. The global dementia and movement disorders market, which encompasses Parkinson's disease dementia, was valued at approximately USD 9.19 billion in 2024 and is predicted to reach around USD 17.66 billion by 2034.
ANAVEX®3-71
- Frontotemporal Dementia: The global Frontotemporal Dementia market is estimated to be valued at USD 12.93 billion in 2025 and is expected to reach USD 19.57 billion by 2032. In the United States, the market size for frontotemporal dementia was USD 60 million in 2024. Across the top seven markets (US, EU4, UK, and Japan), the frontotemporal dementia market reached USD 142.8 million in 2024 and is expected to reach USD 692.7 million by 2035.
AI Analysis | Feedback
Anavex Life Sciences (NASDAQ: AVXL) is positioned for potential future revenue growth over the next 2-3 years, primarily driven by the advancement and prospective commercialization of its pipeline assets for neurodegenerative and neuropsychiatric disorders. The key drivers are centered around regulatory milestones and market penetration of its leading drug candidates. Here are 3-5 expected drivers of future revenue growth: * Commercialization of Blarcamesine (ANAVEX2-73) for Alzheimer's Disease and Rett Syndrome: Blarcamesine (ANAVEX2-73) has demonstrated sustained clinical benefits in early-stage Alzheimer's disease patients over extended periods in open-label extension trials, with data presented at the Alzheimer's Association International Conference 2025. It has also successfully completed Phase 2a, Phase 2b/3 clinical trials for Alzheimer's disease, and Phase 2 and Phase 3 studies in adult patients with Rett syndrome, as well as a Phase 2/3 study in pediatric patients with Rett syndrome. The company is preparing for potential commercialization strategies in Europe, emphasizing the advantages of oral therapies like blarcamesine for broader market penetration due to easier accessibility and less complex administration compared to injectable treatments. The European Medicines Agency (EMA) opinion and subsequent European Commission (EC) decision on blarcamesine for Alzheimer's disease are anticipated. * Development and Potential Launch of ANAVEX3-71 for Schizophrenia: Anavex Life Sciences announced positive topline results from its placebo-controlled Phase 2 clinical study of ANAVEX3-71 for schizophrenia, achieving its primary endpoint of safety and tolerability. Furthermore, the company has successfully developed a once-daily oral tablet formulation for ANAVEX3-71, which exhibits superior pharmacokinetics, potentially improving patient adherence and strengthening its competitive position as the therapy progresses. ANAVEX3-71's mechanism of action, which offers the potential to treat all symptom domains of schizophrenia without the typical side effects of standard antipsychotics, could address a significant unmet medical need in a market projected to reach $11.19 billion by 2030. * Expansion of Blarcamesine (ANAVEX2-73) into New Indications: Beyond Alzheimer's disease and Rett syndrome, Anavex is exploring additional therapeutic applications for blarcamesine. The company was granted a new U.S. patent for ANAVEX2-73 for the treatment of systolic hypertension, expanding its coverage for treatment methods. The market for uncontrolled hypertension alone affects 37 million adults in the U.S., and the global antihypertensive drugs market is predicted to grow significantly, representing a new potential revenue stream if developed for this indication. Additionally, preclinical studies have indicated blarcamesine's potential to treat other CNS disorders, including epilepsy, and it has received a research grant for the development of ANAVEX2-73 for Parkinson's disease. * Advancement of the Precision Medicine Platform: Anavex's precision medicine approach, utilizing genomic biomarkers, aims to identify patient populations most likely to respond to its therapies. This strategy, particularly highlighted in the ANAVEX2-73 Phase 2b/3 study for Alzheimer's disease, could lead to more efficient clinical development and potentially higher success rates in targeted patient groups, optimizing market penetration upon approval. The company has also reported that ANAVEX2-73 treatment resulted in a significant increase in the expression of the SIGMAR1 mRNA biomarker, which correlated with improvements in clinical efficacy endpoints in Rett syndrome, further validating their precision medicine approach.AI Analysis | Feedback
Share Issuance
- Anavex Life Sciences completed a US$150 million at-the-market (ATM) public offering of common stock in August 2025.
- The number of shares outstanding increased from approximately 76.0 million as of November 2021 to around 85.9 million as of August 2025, indicating further share issuances.
- In October 2020, shares were issued under a Sales Agreement and pursuant to a registered direct offering.
Inbound Investments
- Anavex was awarded a $1.0 million research grant from The Michael J. Fox Foundation for Parkinson's Research in January 2021 to develop ANAVEX®2-73 for Parkinson's disease.
Capital Expenditures
- Research and development expenses were $10.0 million for the third quarter of fiscal 2025, a decrease from $11.8 million in the comparable quarter of fiscal 2024.
- Research and development expenses for the second quarter of fiscal 2025 were $9.9 million, compared to $9.7 million for the comparable quarter of fiscal 2024.
- The company's primary focus for capital allocation is on advancing its clinical pipeline for neurodegenerative and neurodevelopmental disorders, supported by a strong cash position that provides a runway of over three years as of June 30, 2025.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to AVXL. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Anavex Life Sciences
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 9.1% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 21.4% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 18.6% |
Price Behavior
Price Behavior
| Market Price | $3.64 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -73.0% | |
| 50 Days | 200 Days | |
| DMA Price | $5.57 | $8.40 |
| DMA Trend | down | down |
| Distance from DMA | -34.6% | -56.6% |
| 3M | 1YR | |
| Volatility | 115.4% | 83.9% |
| Downside Capture | 497.66 | 202.49 |
| Upside Capture | -14.38 | 51.59 |
| Correlation (SPY) | 15.8% | 26.6% |
AVXL Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.15 | 1.49 | 1.61 | 1.65 | 1.20 | 1.52 |
| Up Beta | -3.15 | -2.58 | -1.86 | 0.16 | 1.27 | 1.32 |
| Down Beta | -11.38 | 1.05 | 1.62 | 1.86 | 0.49 | 1.08 |
| Up Capture | 135% | -40% | -21% | 72% | 105% | 467% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 7 | 16 | 24 | 56 | 118 | 344 |
| Down Capture | 803% | 436% | 397% | 270% | 146% | 111% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 12 | 24 | 37 | 67 | 128 | 394 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of AVXL With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| AVXL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -57.8% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 89.9% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.55 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 26.4% | 25.4% | 4.7% | 5.3% | 19.3% | 17.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of AVXL With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| AVXL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -10.6% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 86.7% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.26 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 27.5% | 33.6% | 4.9% | 5.0% | 30.7% | 17.2% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of AVXL With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| AVXL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -6.9% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 86.0% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.31 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 22.9% | 28.2% | 5.4% | 9.6% | 24.3% | 11.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/25/2025 | 12.3% | 48.4% | |
| 5/9/2024 | 4.6% | 21.0% | 4.3% |
| 12/28/2020 | -2.0% | -8.1% | 12.7% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 2 |
| # Negative | 1 | 1 | 1 |
| Median Positive | 8.5% | 34.7% | 8.5% |
| Median Negative | -2.0% | -8.1% | |
| Max Positive | 12.3% | 48.4% | 12.7% |
| Max Negative | -2.0% | -8.1% | |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11252025 | 10-K 9/30/2025 |
| 6302025 | 8122025 | 10-Q 6/30/2025 |
| 3312025 | 5132025 | 10-Q 3/31/2025 |
| 12312024 | 2122025 | 10-Q 12/31/2024 |
| 9302024 | 12232024 | 10-K 9/30/2024 |
| 6302024 | 8062024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 2072024 | 10-Q 12/31/2023 |
| 9302023 | 11272023 | 10-K 9/30/2023 |
| 6302023 | 8082023 | 10-Q 6/30/2023 |
| 3312023 | 5092023 | 10-Q 3/31/2023 |
| 12312022 | 2072023 | 10-Q 12/31/2022 |
| 9302022 | 11282022 | 10-K 9/30/2022 |
| 6302022 | 8092022 | 10-Q 6/30/2022 |
| 3312022 | 5102022 | 10-Q 3/31/2022 |
| 12312021 | 2092022 | 10-Q 12/31/2021 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.